Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2015

Open Access 01-12-2015 | Research

TP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma

Authors: Khadija Rebbani, Agnès Marchio, Sayeh Ezzikouri, Rajaa Afifi, Mostafa Kandil, Olfa Bahri, Henda Triki, Abdellah Essaid El Feydi, Anne Dejean, Soumaya Benjelloun, Pascal Pineau

Published in: Molecular Cancer | Issue 1/2015

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) is characterized by widespread epidemiological and molecular heterogeneity. Previous work showed that in the western part of North Africa, a region of low incidence of HCC, mutations are scarce for this tumor type. As epigenetic changes are considered possible surrogates to mutations in human cancers, we decided, thus, to characterize DNA methylation in HCC from North-African patients.

Methods

A set of 11 loci was investigated in a series of 45 tumor specimens using methylation-specific and combined-bisulfite restriction assay PCR. Results obtained on clinical samples were subsequently validated in liver cancer cell lines.

Results

DNA methylation at tumor suppressor loci is significantly higher in samples displaying chromosome instability. More importantly, DNA methylation was significantly higher in Arg/Arg when compared to Pro/Pro genotype carriers at codon 72 rs1042522 of TP53 (65% vs 20% methylated loci, p = 0.0006), a polymorphism already known to affect somatic mutation rate in human carcinomas. In vitro experiments in cell lines indicated that enzymes controlling DNA methylation were differentially regulated by codon 72 Arg or Pro isoforms of p53. Furthermore, the Arg72-carrying version of p53 was shown to re-methylate DNA more rapidly than the pro-harboring isoform. Finally, Pro-carrying cell lines were shown to be significantly more resistant to decitabine treatment (two-fold, p = 0.005).

Conclusions

Our data suggest that Arg72Pro polymorphism in a WT p53 context may act as a primary driver of epigenetic changes in HCC. It suggests, in addition, that rs1042522 genotype may predict sensitivity to epigenetic-targeted therapy. This model of liver tumorigenesis that associates low penetrance genetic predisposition to epigenetic changes emerges from a region of low HCC incidence and it may, therefore, apply essentially to population living in similar areas. Surveys on populations submitted to highly mutagenic conditions as perinatally-acquired chronic hepatitis B or aflatoxin B1 exposure remained to be conducted to validate our observations as a general model.
Appendix
Available only for authorised users
Literature
1.
Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis. 2010;19:311–7.PubMed
2.
Pineau P, Ezzikouri S, Marchio A, Benazzouz M, Cordina E, Afifi R, et al. Genomic stability prevails in North-African hepatocellular carcinomas. Dig Liv Disease. 2007;39:671–7.CrossRef
3.
Bahri O, Ezzikouri S, Alaya-Bouafif NB, Iguer F, Feydi AE, Mestiri H, et al. First multicenter study for risk factors for hepatocellular carcinoma development in North Africa. World J Hepatol. 2011;27:24–30.
4.
Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5:215–9.CrossRefPubMed
5.
6.
Suriawinata A, Thung SN. Molecular signature of early hepatocellular carcinoma. Oncology. 2010;78:36–9.CrossRefPubMed
7.
Zucman-Rossi J. Molecular classification of hepatocellular carcinoma. Dig Liver Dis. 2010;42:235–41.CrossRef
8.
Lee J, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12:410–6.CrossRefPubMed
9.
Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome Classification of HCC Is Related to Gene Alterations and to New Therapeutic Targets. Hepatology. 2007;45:42–52.CrossRefPubMed
10.
11.
Moribe T, Iizuka N, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H, et al. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer. 2009;125:388–97.CrossRefPubMed
12.
Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010;31:766–76.CrossRefPubMed
13.
Potapova A, Albat C, Hasemeier B, Haeussler K, Lamprecht S, Suerbaum S, et al. Systematic cross-validation of 454 sequencing and pyrosequencing for the exact quantification of DNA methylation patterns with single CpG resolution. BMC Biotechnol. 2011;11:6–15.CrossRefPubMedCentralPubMed
14.
Kim Y, Lee HS. Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology. 2005;48:10–5.CrossRefPubMed
15.
Jin F, Xiong WJ, Jing JC, Feng Z, Qu LS, Shen XZ. Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review. J Cancer Res Clin Oncol. 2011;137:1095–104.CrossRefPubMed
16.
Hu S, Zhao L, Yang J, Hu M. The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases. Tumour Biol. 2014;35:3647–56.CrossRefPubMed
17.
Soussi T, Wiman KG. Shaping genetic alterations in human cancer: The p53 Mutation Paradigm. Cancer Cell. 2007;12:303–12.CrossRefPubMed
18.
Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, et al. Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer. 2007;97:1260–5.CrossRefPubMedCentralPubMed
19.
Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology. 2008;47:908–18.CrossRefPubMedCentralPubMed
20.
Rauhala HE, Porkka KP, Saramäki OR, Tammela TL, Visakorpi T. Clusterin is epigenetically regulated in prostate cancer. Int J Cancer. 2008;123:1601–9.CrossRefPubMed
21.
Iliopoulos D, Satra M, Drakaki A, Poultsides GA, Tsezou A. Epigenetic regulation of hTERT promoter in hepatocellular carcinomas. Int J Oncol. 2009;34:391–9.PubMed
22.
Herath NI, Purdie DM, Kew MC, Smith JL, Young J, Leggett BA, et al. Varying etiologies lead to different molecular changes in Australian and South African hepatocellular carcinomas. Int J Oncol. 2009;35:1081–9.CrossRefPubMed
23.
Formeister EJ, Tsuchiya M, Fujii H, Shpyleva S, Pogribny IP, Rusyn I. Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat Res. 2010;692:26–33.CrossRefPubMedCentralPubMed
24.
Lambert MP, Paliwal A, Vaissière T, Chemin I, Zoulim F, Tommasino M, et al. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol. 2011;54:705–15.CrossRefPubMed
25.
Oster B, Thorsen K, Lamy P, Wojdacz TK, Hansen LL, Birkenkamp-Demtröder K, et al. Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer. 2011;129:2855–66.CrossRefPubMed
26.
Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology. 2012;56:994–1003.CrossRefPubMed
27.
Jain S, Xie L, Boldbaatar B, Lin SY, Hamilton JP, Meltzer SJ, et al. Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis. Hepatol Res. 2014; doi: 10.1111/hepr.12449.
28.
Kuo CC, Lin CY, Shih YL, Hsieh CB, Lin PY, Guan SB, et al. Frequent methylation of HOXA9 gene in tumor tissues and plasma samples from human hepatocellular carcinomas. Clin Chem Lab Med. 2014;52:1235–45.CrossRefPubMed
29.
Michailidi C, Soudry E, Brait M, Maldonado L, Jaffe A, Ili-Gangas C, et al. Genome-wide and gene-specific epigenomic platforms for hepatocellular carcinoma biomarker development trials. Gastroenterol Res Pract. 2014;2014:597164.CrossRefPubMedCentralPubMed
30.
Ezzikouri S, El Feydi AE, Afifi R, El Kihal L, Benazzouz M, Hassar M, et al. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case–control analysis in a Moroccan population. Cancer Detect Prev. 2009;32:380–5.CrossRefPubMed
31.
Vogelstein B, Fearon E, Kern S, Hamilton S, Preisenger AC, Nakamura Y, et al. Allelotype of colorectal carcinomas. Science. 1989;244:207–11.CrossRefPubMed
32.
Nyce J. Drug-induced DNA, hypermethylation and drug resistance in human tumors. Cancer Res. 1989;49:5829–36.PubMed
33.
34.
Jeong B, Hu W, Belyi V, Rabadan R, Levine AJ. Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB J. 2010;24:1347–53.CrossRefPubMed
35.
36.
Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–100.PubMedCentralPubMed
37.
Melnikov A, Gartenhaus RB, Levenson AS, Motchoulskaia NA, Levenson Chernokhvostov VV. MSRE-PCR for analysis of gene-specific DNA methylation. Nucleic Acids Res. 2005;33:e93.CrossRefPubMedCentralPubMed
38.
Estève P, Chin HG, Pradhan S. Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. Proc Natl Acad Sci U S A. 2005;102:1000–5.CrossRefPubMedCentralPubMed
39.
Ezzikouri S, Pineau P, Benjelloun S. Hepatitis B virus in the Maghreb region: from epidemiology to prospective research. Liver Int. 2013;33:811–9.CrossRefPubMed
40.
Ezzikouri S, Pineau P, Benjelloun S. Hepatitis C virus infection in the Maghreb region. J Med Virol. 2013;85:1542–9.CrossRefPubMed
41.
el Tazi M, Essadi I, M'rabti H, Touyar A, Errihani PH. Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. N Am J Med Sci. 2011;3:167–75.CrossRefPubMedCentral
42.
Cherradi Y, Afifi R, Benbrahim H, Essamri W, Benelbarhdadi I, Ajana FZ, et al. Predictors of developing hepatocellular carcinoma in treated HCV-carriers in Morocco according to University Hospital experience. ISRN Hepatology. 2013. Article ID 438306: doi:10.1155/2013/438306.
43.
Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, Gouysse G, McKay-Chopin S, Tavtigian SV, et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One. 2010;5:e9749.CrossRefPubMedCentralPubMed
44.
Shen L, Kondo Y, Rosner G, Xiao L, Hernandez N, Vilaythong J, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005;97:1330–8.CrossRefPubMed
45.
46.
Lou C, Du Z, Yang B, Gao Y, Wang Y, Fang S. Aberrant DNA methylation profile of hepatocellular carcinoma and surgically resected margin. Cancer Sci. 2009;100:996–1004.CrossRefPubMed
47.
Nishida N, Nishimura T, Nagasaka T, Ikai I, Goel A, Boland CR. Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. Cancer Res. 2007;67:4586–94.CrossRefPubMed
48.
Hanel W, Moll UM. Links between mutant p53 and genomic instability. J Cell Biochem. 2012;113:433–9.CrossRefPubMed
49.
Nasr A, Nutini M, Palombo B, Guerra E, Alberti S. Mutations of TP53 induce loss of DNA methylation and amplification of the TROP1 gene. Oncogene. 2003;22:1668–77.CrossRefPubMed
50.
Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The Codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–65.CrossRefPubMed
51.
Zhu Z, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol. 2005;11:289–92.CrossRefPubMedCentralPubMed
52.
Levine A, Tomasini R, McKeon FD, Mak TW, Melino G. The p53 family: guardians of maternal reproduction. Nat Rev Mol Cell Biol. 2011;12:259–65.CrossRefPubMed
53.
54.
Tyner S, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, et al. P53 mutant mice that display early ageing-associated phenotypes. Nature. 2002;415:45–53.CrossRefPubMed
55.
Ørsted D, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med. 2007;204:1295–301.CrossRefPubMedCentralPubMed
56.
Lo HW, Stephenson L, Cao X, Milas M, Pollock R, Ali-Osman F. Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene. Mol Cancer Res. 2008;6:843–50.CrossRefPubMedCentralPubMed
57.
Calabrese V, Mallette FA, Deschênes-Simard X, Ramanathan S, Gagnon J, Moores A, et al. SOCS1 links cytokine signaling to p53 and senescence. Mol Cell. 2009;36:754–67.CrossRefPubMed
58.
59.
60.
Coppedè F. Epigenetic biomarkers of colorectal cancer: Focus on DNA methylation. Cancer Lett. 2014;342:238–47.CrossRefPubMed
61.
Kojima C, Ramirez D, Tokar E, Himeno S, Drobná Z, Stýblo M, et al. Requirement of arsenic biomethylation for oxidative DNA damage. J Natl Cancer Inst. 2009;101:1670–81.CrossRefPubMedCentralPubMed
62.
Chun J, Bae J, Park T, Kim J, Park B, Cheong H, et al. Putative association of DNA methyltransferase 1 (DNMT1) polymorphisms with clearance of HBV infection. BMB Rep. 2009;42:834–9.CrossRefPubMed
63.
Zhao C, Yan F, Wu H, Qiao F, Qiu X, Fan H. DNMT3A–448A > G polymorphism and the risk for hepatocellular carcinoma. Biomed Rep. 2013;1:664–8.PubMedCentralPubMed
64.
Bhutani N, Brady JJ, Damian M, Sacco A, Corbel SY, Blau HM. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature. 2010;463:1042–7.CrossRefPubMedCentralPubMed
65.
Wang Y, Kamarova Y, Shen KC, Jiang Z, Hahn MJ, Wang Y, et al. DNA methyltransferase-3a interacts with p53 and represses p53-mediated gene expression. Cancer Biol Ther. 2005;4:1138–43.CrossRefPubMed
66.
Hervouet E, Vallette FM, Cartron PF. Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation. Epigenetics. 2009;4:487–99.CrossRefPubMed
67.
Lin R, Wu C, Chang J, Juan L, Hsu H, Chen C, et al. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res. 2010;70:5807–17.CrossRefPubMed
68.
Peterson E, Bögler O, Taylor S. p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. Cancer Res. 2003;63:6579–82.PubMed
69.
Le Gac G, Estève PO, Ferec C, Pradhan S. DNA damage-induced down-regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine-5) methyltransferase 1. J Biol Chem. 2006;281:24161–70.CrossRefPubMed
70.
Cowan L, Talwar S, Yang AS. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics. 2010;2:71–86.CrossRefPubMed
71.
Boumber Y, Issa JP. Epigenetics in cancer: what's the future? Oncology (Williston Park). 2011;25:220–6. 228.
72.
Pineau P, Marchio A, Battiston C, Cordina E, Russo A, Terris B, et al. Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutat Res. 2008;653:6–13.CrossRefPubMed
73.
Pineau P, Nagai H, Prigent S, Wei Y, Gyapay G, Weissenbach J, et al. Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma. Oncogene. 1999;18:3127–34.CrossRefPubMed
74.
Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El Kihal L, Afifi R, et al. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res. 2007;37:748–54.CrossRefPubMed
75.
Yang A, Estécio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res. 2004;32:e38.CrossRefPubMedCentralPubMed
76.
Du Y, Carling T, Fang W, Piao Z, Sheu JC, Huang S. Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res. 2001;61:8094–9.PubMed
77.
Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 2001;61:3877–81.PubMed
78.
Kumari A, Srinivasan R, Vasishta RK, Wig JD. Positive regulation of human telomerase reverse transcriptase gene expression and telomerase activity by DNA methylation in pancreatic cancer. Ann Surg Oncol. 2009;16:1051–9.CrossRefPubMed
79.
Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28:29–35.PubMed
80.
House M, Guo M, Iacobuzio-Donahue C, Herman J. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis. 2003;24:193–8.CrossRefPubMed
81.
Sunami E, Shinozaki M, Higano CS, Wollman R, Dorff TB, Tucker SJ, et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem. 2009;55:559–67.CrossRefPubMed
82.
Pineau P, Marchio A, Nagamori S, Seki S, Tiollais P, Dejean A. Homozygous Deletion scanning in Hepatobiliary Tumor Cell Lines reveals Alternative Pathways for Liver Carcinogenesis. Hepatology. 2003;37:852–61.CrossRefPubMed
83.
Seeler J, Marchio A, Losson R, Desterro JM, Hay RT, Chambon P, et al. Common properties of nuclear body protein SP100 and TIF1alpha chromatin factor: role of SUMO modification. Mol Cell Biol. 2001;21:3314–24.CrossRefPubMedCentralPubMed
84.
Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. MiR-221 Overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:264–9.CrossRefPubMedCentralPubMed
85.
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:34.CrossRef
86.
Hua D, Hu Y, Wu YY, Cheng ZH, Yu J, Du X, et al. Quantitative methylation analysis of multiple genes using methylation-sensitive restriction enzyme-based quantitative PCR for the detection of hepatocellular carcinoma. Exp Mol Pathol. 2011;91:455–60.CrossRefPubMed
Metadata
Title
TP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma
Authors
Khadija Rebbani
Agnès Marchio
Sayeh Ezzikouri
Rajaa Afifi
Mostafa Kandil
Olfa Bahri
Henda Triki
Abdellah Essaid El Feydi
Anne Dejean
Soumaya Benjelloun
Pascal Pineau
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2015
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-015-0340-2

Other articles of this Issue 1/2015

Molecular Cancer 1/2015 Go to the issue

Research

Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells

Review

Genetic instability in the tumor microenvironment: a new look at an old neighbor

Research

Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells

Letter to the Editor

Identification of ANLN as ETV6 partner gene in recurrent t(7;12)(p15;p13): a possible role of deregulated ANLN expression in leukemogenesis

Research

Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma

Research

Prognostic relevance of acquired uniparental disomy in serous ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits